Sevim Bavbek

Sevim Bavbek

Auto-generated profile, based on publicly available information

Sevim Bavbek

Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2013 in Allergy
Verified
Journal Article
Open access
PDF file
MKM. L. Kowalski
M. L. Kowalski
RAR. Asero
R. Asero
SBS. Bavbek
S. Bavbek
MBM. Blanca
M. Blanca
NBN. Blanca‐Lopez
N. Blanca‐Lopez
JMJ. Makowska
J. Makowska
Hypersensitivity reactions to aspirin (acetylsalicylic acid) and other nonsteroidal anti‐inflammatory drugs (NSAIDs) constitute only a subset of all adverse reactions to these drugs, but due to their severity pose a significant burden to patients and are a challenge to the allergist. In susceptible individuals, NSAIDs induce a wide spectrum of hypersensitivity reactions with various timing, organ manifestations, and severity, involving either immunological (allergic) or nonimmunological mechanisms. Proper classification of reactions based on clinical manifestations and suspected mechanism is a prerequisite for the implementation of rational diagnostic procedures and adequate patient management. This document, prepared by a panel of experts from the European Academy of Allergy and Clinical Immunology Task Force on NSAIDs Hypersensitivity, aims at reviewing the current knowledge in the field and proposes uniform definitions and clinically useful classification of hypersensitivity reactions to NSAIDs. The document proposes also practical algorithms for the diagnosis of specific types of NSAIDs hypersensitivity (which include drug provocations, skin testing and in vitro testing) and provides, when data are available, evidence‐based recommendations for the management of hypersensitive patients, including drug avoidance and drug desensitization.

14 February 2011 in Allergy
Verified
Journal Article
Open access
PDF file
MKM. L. Kowalski
M. L. Kowalski
JMJ. S. Makowska
J. S. Makowska
MBM. Blanca
M. Blanca
SBS. Bavbek
S. Bavbek
GBG. Bochenek
G. Bochenek
KBK. Brockow
K. Brockow
To cite this article: Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska‐Mogilnicka E, Romano A, Sanchez‐Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti‐inflammatory drugs (NSAIDs) – classification, diagnosis and management: Review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66: 818–829. Abstract Nonsteroidal anti‐inflammatory drugs (NSAIDs) are responsible for 21–25% of reported adverse drug events which include immunological and nonimmunological hypersensitivity reactions. This study presents up‐to‐date information on pathomechanisms, clinical spectrum, diagnostic tools and management of hypersensitivity reactions to NSAIDs. Clinically, NSAID hypersensitivity is particularly manifested by bronchial asthma, rhinosinusitis, anaphylaxis or urticaria and variety of late cutaneous and organ‐specific reactions. Diagnosis of hypersensitivity to a NSAID includes understanding of the underlying mechanism and is necessary for prevention and management. A stepwise approach to the diagnosis of hypersensitivity to NSAIDs is proposed, including clinical history, in vitro testing and/or provocation test with a culprit or alternative drug depending on the type of the reaction. The diagnostic process should result in providing the patient with written information both on forbidden and on alternative drugs.

14 September 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
MKMarek L. Kowalski
Marek L. Kowalski
IAIoana Agache
Ioana Agache
SBSevim Bavbek
Sevim Bavbek
ABArzu Bakirtas
Arzu Bakirtas
MBMiguel Blanca
Miguel Blanca
AWAleksandra Wardzyńska
Aleksandra Wardzyńska

1 January 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
WBWilliam W Busse
William W Busse
EBEugene R Bleecker
Eugene R Bleecker
JFJ Mark FitzGerald
J Mark FitzGerald
GFGary T Ferguson
Gary T Ferguson
PBPeter Barker
Peter Barker
LLLan Le
Lan Le

29 September 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
MPMauro Pagani
Mauro Pagani
SBSevim Bavbek
Sevim Bavbek
EAEmilio Alvarez‐Cuesta
Emilio Alvarez‐Cuesta
ADAdile Berna Dursun
Adile Berna Dursun
PBPatrizia Bonadonna
Patrizia Bonadonna
SSSoledad Sanchez Sanchez
Soledad Sanchez Sanchez

1 January 2012 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
IAIoana Agache
Ioana Agache
SBSevim Bavbek
Sevim Bavbek
BBBeatrice M Bilo
Beatrice M Bilo
FBFulvio Braido
Fulvio Braido
CACezmi A Akdis
Cezmi A Akdis
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21stcentury.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a non‐profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients’ organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re‐categorize clinical syndromes into more coherent, uniform and treatment‐responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient‐oriented diagnostic and treatment protocols. Several allergic diseases require well‐controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult‐to‐manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.